Innate Pharma Announces Conference Call and Webcast for 2021 First Quarter Business Update
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tuesday, May 11, 2021 at 3 p.m...Innate Pharma files its 2020 Universal Registration Document (document d’enregistrement universel) and 2020 Annual Report on Form 20-F
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2020 Universal Registration Document (Document d’enregistrement...Innate Pharma to Hold its Annual General Meeting of Shareholders on May 28, 2021
The Annual General Meeting will be broadcasted live by the Company Shareholders are invited to vote at the General Meeting either by mail or by proxy Innate Pharma SA (Euronext Paris: IPH – ISIN...Number of Shares and Voting Rights of Innate Pharma as of April 1, 2021
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation...Innate Pharma reports Full Year 2020 financial results and business update
• Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides and peripheral T-cell lymphoma • Company’s...Innate Pharma announces conference call and webcast for Full Year 2020 financial results
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, March 18, 2021 at 2 p.m...Number of shares and voting rights of Innate Pharma as of February 1, 2021
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation...Innate Pharma to participate in the 10th annual SVB Leerink Global Healthcare Conference
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the...Innate Pharma advances lacutamab clinical development program
TELLOMAK trial progresses as cohort 2 of KIR3DL2-expressing mycosis fungoides patients advances to Stage 2 earlier than anticipated Company to initiate two new clinical trials to investigate lacutamab...Innate Pharma to host key opinion leader discussion on the potential role of lacutamab across T-cell lymphomas
Virtual event to take place at 2:00 p.m. CET / 8:00 a.m. ET on Tuesday, February 9, 2021 Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today...
